康希諾、智飛生物領漲疫苗股 國內多點零星病例再現
格隆匯5月17日丨A股疫苗股普漲,其中,康希諾、智飛生物、沃森生物漲超4%,西藏藥業漲超3%,康華生物漲近3%,華北製藥和華蘭生物漲超1%。時隔近一個月,國內多點零星病例再現。值得注意的是,安徽、遼寧兩地確診病例此前都未接種新冠疫苗。本土疫情的出現,再次提示通過疫苗接種儘早構築免疫屏障刻不容緩。目前,全國已累計報吿接種新冠疫苗3.9億劑次。中國疾控中心主任高福近日在接受採訪時表示,預計到明年,中國將有9億-10億人接種新冠疫苗,可達到實現全民免疫的標準。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.